ArticleNature medicine2025
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.
Abstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan.Frontiers in immunology · 2026Pooled it
- Antibody-drug conjugates in advanced small-cell lung cancer: a systematic review and single-arm meta-analysis of later-line monotherapy.Frontiers in immunology · 2026Pooled it
- Trial
- Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors.Cancer research communications · 2025Trial
- Antibody-Drug Conjugates in Biliary Tract Cancer: Current Evidence, Emerging Targets, and Future Directions.Current oncology reports · 2026Review
- Antibody-drug conjugates in lung cancer: clinical development, therapeutic advances, and emerging challenges.Cancer chemotherapy and pharmacology · 2026Review
- A modular framework for antibody-drug conjugate biomarkers.Nature reviews. Clinical oncology · 2026Review
- The Osteosarcoma Tumor Microenvironment: Supportive of Tumor Progression, Hostile to Immunity, but Therapeutically Targetable.Cancers · 2026Review
- [Personalized drug therapy of metastatic lung cancer].Innere Medizin (Heidelberg, Germany) · 2026Review
- Antibody-drug conjugates in breast cancer: redefining targeted therapy.The Journal of clinical investigation · 2026Review
- Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.Translational cancer research · 2026Article
- Nasopharyngeal carcinoma: epidemiology, risk factors, signaling pathways, clinical features, diagnosis, and management.Molecular biomedicine · 2026Review
- Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors.Journal of hematology & oncology · 2026Review
- Antibody-Drug Conjugates in the Treatment of Esophageal Cancer.Current treatment options in oncology · 2026Review
- Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial.EClinicalMedicine · 2026Article
- Review
- Advances in the Research of Nasopharyngeal Carcinoma: A Perspective.Cancer innovation · 2026Review
- Targeting TROP2 and Exploiting AUNIP as a Determinant of ADC Cytotoxicity and Chemosensitivity in HNSCC and ESCA Cancers.Molecular carcinogenesis · 2026Article
- SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.Nature medicine · 2026Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Yuxiang Ma *Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.ORCID http://orcid.org/0000-0003-1173-8441
Yunpeng Yang *Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Yan Huang *Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Wenfeng Fang *Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Jinhui Xue *Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Xiangjiao Meng *Department of Chest Radiotherapy IV, Shandong Cancer Hospital and Institute, Jinan, China.
Yun Fan *Department of Chest Medicine, Zhejiang Cancer Hospital, Hangzhou, China.ORCID http://orcid.org/0000-0003-1755-0175
Siqing Fu *The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1933-0419
Lin WuDepartment of Internal Thoracic, Hunan Cancer Hospital, Changsha, China.ORCID http://orcid.org/0000-0001-7078-7767
Yulong ZhengDepartment of Medical Oncology/Clinical Pharmacy Research Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jian LiuDepartment of Medical Oncology/Clinical Pharmacy Research Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhihua LiuDepartment of Thoracic Tumor Radiotherapy I, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wu ZhuangDepartment of Thoracic Oncology, Fujian Cancer Hospital, Fuzhou, China.
Seth RosenHematology Oncology Associates of the Treasure Coast, Port Saint Lucie, FL, USA.
Song QuDepartment of Radiotherapy, Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China.
Bihui LiDepartment of Medical Oncology, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
Mingjun LiDepartment of Oncology II, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yanqiu ZhaoDepartment of Respiratory Medicine I, Henan Cancer Hospital, Zhengzhou, China.
Shujun YangDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Yinghua JiDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
David SommerhalderNEXT Oncology, San Antonio, TX, USA.ORCID http://orcid.org/0000-0002-7033-9064
Suxia LuoPhase I Clinical Trial Center, Henan Cancer Hospital, Zhengzhou, China.
Kunyu YangDepartment of Head and Neck Oncology, Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jingao LiDepartment of Head and Neck Radiotherapy II, Jiangxi Cancer Hospital (Jiangxi Second People's Hospital), Nanchang, China.
Dongqing LvDepartment of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Taizhou, China.
Peng ZhangDepartment of Radiotherapy, Sichuan Cancer Hospital, Chengdu, China.
Yuanyuan ZhaoDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Shaodong HongDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Yang ZhangDepartment of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Shen ZhaoDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Steve ChinMediLink Therapeutics (Suzhou) Co., Ltd., Suzhou, China.
Xian ZhangMediLink Therapeutics (Suzhou) Co., Ltd., Suzhou, China.
Wei LianMediLink Therapeutics (Suzhou) Co., Ltd., Suzhou, China.ORCID http://orcid.org/0009-0003-8415-6001
Jiaqiang CaiMediLink Therapeutics (Suzhou) Co., Ltd., Suzhou, China.
Tongtong XueMediLink Therapeutics (Suzhou) Co., Ltd., Suzhou, China. tony@medilinkthera.com.ORCID http://orcid.org/0009-0000-5961-7724
Li ZhangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. zhangli@sysucc.org.cn.ORCID http://orcid.org/0000-0003-0595-0761
Hongyun ZhaoDepartment of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. zhaohy@sysucc.org.cn.ORCID http://orcid.org/0000-0002-1251-3888
Funding
National Natural Science Foundation of China (National Science Foundation of China) 82272789National Natural Science Foundation of China (National Science Foundation of China) 82473346
Abstract
Antibody-drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker. Here we report the findings from a large-scale, global, multicenter, phase 1 trial evaluating the safety, pharmacokinetics and preliminary efficacy of YL201 in patients with advanced solid tumors refractory to standard therapies. The trial included a dose-escalation part (phase 1) and a dose-expansion part (phase 1b). A total of 312 patients were enrolled across multiple tumor types, including extensive-stage small cell lung cancer (ES-SCLC), nasopharyngeal carcinoma (NPC), non-small cell lung cancer, esophageal squamous cell carcinoma and other solid tumors. The maximum tolerated dose was determined to be 2.8 mg kg
Indexed as
B7 AntigensImmunoconjugatesNeoplasmsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedNasopharyngeal CarcinomaB7 AntigensCD276 protein, humanImmunoconjugates
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.